News | May 28, 2024
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Launch of 20 new medicines expected by 2030
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Achira is engaged in development and commercialization of PoC medical test kits in India
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subscribe To Our Newsletter & Stay Updated
